These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34234243)

  • 1. BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy.
    Hahn L; Lim H; Dusyk T; Sabry W; Elemary M; Stakiw J; Danyluk P; Bosch M
    Sci Rep; 2021 Jul; 11(1):14071. PubMed ID: 34234243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.
    Wu R; Ma L
    Cell Transplant; 2023; 32():9636897231179364. PubMed ID: 37350429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation.
    Eltelbanei MA; El-Bassiouny NA; Abdalla MS; Khalaf M; Werida RH
    BMC Cancer; 2024 Aug; 24(1):1002. PubMed ID: 39134959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.
    Saleh K; Danu A; Koscielny S; Legoupil C; Pilorge S; Castilla-Llorente C; Ghez D; Lazarovici J; Michot JM; Khalife-Saleh N; Lapierre V; Alenxandrova K; Arfi-Rouche J; Bourhis JH; Ribrag V
    Leuk Lymphoma; 2018 Nov; 59(11):2580-2587. PubMed ID: 29164977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers.
    Hueso T; Gastinne T; Garciaz S; Tchernonog E; Delette C; Casasnovas RO; Durot E; Houot R; Tessoulin B; Tournilhac O; Malak S; Gyan E; Fornecker LM; Abraham J; Delapierre B; Peyrade F; Lemal R; Gressin R; Chantepie S; Borel C; Morello R; Bouabdallah K; Ibrahim A; Bouabdallah R; Le Gouill S; Damaj G
    Bone Marrow Transplant; 2020 Jun; 55(6):1076-1084. PubMed ID: 31953532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study.
    Costes-Tertrais D; Hueso T; Gastinne T; Thieblemont C; Oberic L; Bouabdallah K; Garciaz S; Tchernonog E; Dartigeas C; Ribrag V; Fogarty P; Casasnovas RO; Houot R; Delette C; Malak S; Fornecker LM; Gressin R; Damaj G; Le Gouill S
    Bone Marrow Transplant; 2022 Apr; 57(4):627-632. PubMed ID: 35149851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous hematopoietic stem cell transplantation.
    Plante MÉ; Feng X; Boudreault JS
    Leuk Lymphoma; 2023; 64(7):1234-1242. PubMed ID: 37154396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation.
    Frankiewicz A; Saduś-Wojciechowska M; Najda J; Czerw T; Mendrek W; Sobczyk-Kruszelnicka M; Soska K; Ociepa M; Hołowiecki J; Giebel S
    Contemp Oncol (Pozn); 2018; 22(2):113-117. PubMed ID: 30150889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BeEAM vs. BEAM: evaluating conditioning regimens for autologous stem cell transplantation in patients with relapsed or refractory DLBCL.
    Wang R; Shangguan X; Zhu Z; Cong D; Bai Y; Zhang W
    Ann Hematol; 2024 Jul; 103(7):2455-2462. PubMed ID: 38809456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
    Josting A; Reiser M; Wickramanayake PD; Rueffer U; Draube A; Söhngen D; Tesch H; Wolf J; Diehl V; Engert A
    Leuk Lymphoma; 2000 Mar; 37(1-2):115-23. PubMed ID: 10721775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas.
    Sakellari I; Mallouri D; Batsis I; Apostolou C; Konstantinou V; Abela EM; Douka V; Marvaki A; Karypidis K; Iskas M; Baliakas P; Kaloyannidis P; Yannaki E; Sotiropoulos D; Kouvatseas G; Smias C; Anagnostopoulos A
    Leuk Lymphoma; 2015; 56(11):3071-81. PubMed ID: 25760637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple Myeloma.
    Solomon SR; Brown S; Shegda N; Jackson KC; Zhang X; Bashey A; Holland HK; Morris LE; Solh M
    Transplant Cell Ther; 2022 Aug; 28(8):486.e1-486.e7. PubMed ID: 35598842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Toxicity and Efficacy of Four Different Conditioning Regimens for Autologous Hematopoietic Cell Transplantation in Patients With Lymphoma: Impact of Drug Shortages in a Resource-Constrained Country.
    Carranza J; Fatobene G; Otuyama LJ; Dos Santos JG; Cordeiro AC; Mariano L; Rocha V
    Transplant Cell Ther; 2024 Oct; 30(10):1003.e1-1003.e9. PubMed ID: 39097096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective.
    Reid RM; Baran A; Friedberg JW; Phillips GL; Liesveld JL; Becker MW; Wedow L; Barr PM; Milner LA
    Cancer Med; 2016 Nov; 5(11):3059-3067. PubMed ID: 27699999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol.
    Ramzi M; Mohamadian M; Vojdani R; Dehghani M; Nourani H; Zakerinia M; Haghighinejad H
    Exp Clin Transplant; 2012 Apr; 10(2):163-7. PubMed ID: 22432762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
    Cashen AF; Fletcher T; Ceriotti C; Gao F; Ghobadi A; Vij R; Stockerl-Goldstein K; DiPersio J; Abboud C
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2155-2158. PubMed ID: 27575541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A low thrombospondin-1 serum concentration is related to increased bacteremia risk in lymphoma patients treated with BeEAM/BEAM conditioning regimen and autologous stem cell transplantation.
    Kościelny K; Mikulski D; Nowicki M; Wyka K; Misiewicz M; Perdas E; Wierzbowska A; Fendler W
    Transpl Infect Dis; 2024 Feb; 26(1):e14212. PubMed ID: 38112043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma.
    Grisariu S; Shapira MY; Or R; Avni B
    Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):272-279. PubMed ID: 29500148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.
    Visani G; Malerba L; Stefani PM; Capria S; Galieni P; Gaudio F; Specchia G; Meloni G; Gherlinzoni F; Giardini C; Falcioni S; Cuberli F; Gobbi M; Sarina B; Santoro A; Ferrara F; Rocchi M; Ocio EM; Caballero MD; Isidori A
    Blood; 2011 Sep; 118(12):3419-25. PubMed ID: 21816830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study.
    Musso M; Scalone R; Marcacci G; Lanza F; Di Renzo N; Cascavilla N; Di Bartolomeo P; Crescimanno A; Perrone T; Pinto A
    Bone Marrow Transplant; 2010 Jul; 45(7):1147-53. PubMed ID: 19898504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.